The US FTC approves modifications to a pharmaceutical company’s divestiture agreement in the context of its previous acquisition of its competitor (Bristol Meyers Squibb / Celgene)

FTC Approves Modifications to Bristol Meyers Squibb Divestiture Agreement* The Federal Trade Commission has approved certain modifications to Bristol Meyers Squibb’s, or BMS’s, Divestiture Agreements

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

US Federal Trade Commission, The US FTC approves modifications to a pharmaceutical company’s divestiture agreement in the context of its previous acquisition of its competitor (Bristol Meyers Squibb / Celgene), 12 November 2021, e-Competitions November 2021 - II, Art. N° 103565

Visites 109

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues